Table 1

Characteristics of targeted anticancer medication in the intervention group and comparison group

NoGeneric nameLaunch time in ChinaIndication
Intervention group
1RituximabApril 2000Lymphoma
2TrastuzumabSeptember 2002Breast cancer; stomach cancer
3BortezomibFebruary 2005Multiple myeloma; lymphoma
4Recombinant Human EndostatinSeptember 2005Lung cancer
5ErlotinibApril 2006Lung cancer
6SorafenibSeptember 2006Liver cancer; kidney cancer; thyroid cancer
7NimotuzumabApril 2008Nasopharynx cancer
8BevacizumabFebruary 2010Colorectal cancer; lung cancer
9FulvestrantJune 2010Breast cancer
10LapatinibJanuary 2013Breast cancer
11EverolimusJanuary 2013Brain cancer; kidney cancer; pancreatic neuroendocrine tumor
12LenalidomideJanuary 2013Multiple myeloma
13ApatinibOctober 2014Stomach cancer
14ChidamideDecember 2014Lymphoma
15AbirateroneMay 2015Prostate cancer
Comparison group
1CetuximabJuly 2006Colorectal cancer
2SunitinibOctober 2007Kidney cancer; stomach cancer; pancreatic neuroendocrine tumor
3PegaspargaseJanuary 2009Leukaemia
4NilotinibJuly 2009Leukaemia
5CrizotinibJanuary 2013Lung cancer
6AxitinibApril 2015Kidney cancer